​The domestic IV therapy equipment market, currently valued at $2.7 billion, continues to grow steadily. Due to a number of powerful demographic factors, over the mid to long-term, domestic demand for such equipment is very likely to increase. Most significantly among these is the accelerated “graying of America”: In 1900, only one of every twenty-five U.S. residents was aged 65+, 120 years later, that proportion has skyrocketed to almost one out of six. Only twenty years from now, in 2040, one in every five Americans will be elderly.

Given the strong correlation between advanced age and the conditions that are treated by IV therapies, intravenous medicine is likely to become even more prevalent than it is today. Foremost among those conditions is cancer. In 2017, the last year for which United States Cancer Statistics (USCS, a division of the CDC) conducted its analysis, a total of 1,701,315 new cancer cases were reported across the country. Just seven years prior, in 2010, 1,529,560 cancer cases were diagnosed in the United States. 

“The rising incidence of chronic diseases,” the analytical firm Markets and Markets observed with respect to the IV therapy equipment market, “…and the growing use of IV therapy in their treatment are expected to drive the growth of this market in the coming years.” Aside from cancer, some of the other prevalent chronic diseases that often involve treatment with IV fluids are heart disease, stroke, chronic respiratory diseases (CRDs) and diabetes. Collectively, those conditions affect over 75 million Americans. 

The treatment of some of the most pervasive chronic conditions in the country, affecting tens of millions of Americans, relies at least partly on treatment with IV fluids and, consequently would stand to benefit from use of the Spike Guard. However, while the ongoing growth of the incidence of various chronic conditions is considered to be the primary driver of IV use in the United States, the common uses of IV therapy extends beyond chronic conditions to patients admitted for trauma, burns or certain types of operations. 

In fact, even the current Covid-19 pandemic has some relevance in this regard as a recent study published by Harvard Medical School highlighted experimental Covid-19 treatments involving high doses of vitamin C administered intravenously, not unlike those administered to colon cancer patients. So, IV therapy has never been more prevalent which also means that the problem addressed by the Spike Guard has never been more relevant and pressing.